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Influenza and an agIng 
PoPulatIon
Influenza is a disease of viral origin com-
monly associated with a rapid onset of 
symptoms which may include fever, chills, 
fatigue, headache, joint pain, and nasal 
congestion. But the illness may be asymp-
tomatic in many individuals facilitating 
the spread of the virus. In older individu-
als the most common presenting symptom 
may be a cough. The incidence of fever at 
presentation in older individuals is much 
less common than in younger individuals 
(McElhaney, 2005). Global estimates are 
that influenza infections cause between 
250,000 and 350,000 deaths per year but 
that there are between 3 and 5 million severe 
cases per year (http://www.who.int/medi-
acentre/factsheets/fs211/en/). Influenza 
is commonly thought to be a disease of 
limited duration, but in older individuals 
it may lead to a period of prolonged bed 
rest. Because long periods of bed rest are 
associated with a loss of aerobic capacity 
(1% per week whilst bedridden), a loss of 
muscle capacity (5% per week), and a loss of 
bone density (∼1% per week) this may leave 
a previously healthy older individual as a 
weak frail person dependent on assistance 
from others for their normal activities of 
daily living (McElhaney, 2005). Moreover a 
common complication of influenza is sec-
ondary bacterial infection which greatly 
increases the likelihood of complications 
such as pneumonia and contributes to a 
poorer prognosis (Rothberg et al., 2008).
Influenza is mostly transmitted by aero-
sol, so infection is very dependent on social 
interaction. A diameter of ∼1 m around an 
individual is the area within which they 
can become infected by the airborne route 
(Lofgren, 2011). A potential second route 
of infection is through self-infection aris-
ing because many individuals frequently 
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Previous vaccine development has been 
driven mainly by policies and concerns 
around childhood, with the aim of pre-
venting premature death amongst young 
children from infectious disease and stop-
ping them from acting as carriers. Whilst 
this is important, the face of the world has 
changed recently and the problem has now 
to be extended to include the protection 
of a vulnerable aging population. Here we 
present the case for a need to develop a 
prophylactic regimen for older individuals 
which features vaccination at the center of 
a portfolio of treatments.
Advances in medical, social, and eco-
nomic conditions have resulted in human 
population growth and an ever-extending 
life expectancy such that for the first time 
in our history the world population will 
soon have more people over the age of 65 
than under the age of 5. The development 
of antibiotic therapy, progresses in vaccine 
technology combined with mass vaccina-
tion programs and government schemes 
to improve economic and social well-being 
mean that the majority of individuals over 
the age of 65 are currently physically more 
active than their counterparts a few decades 
ago (Michel et al., 2008). Moreover these 
individuals now travel more than either 
their parents or grandparents. The world is 
now so closely networked that any pathogen 
may spread across the globe within hours, 
as was observed with the recent H5N1 
and H1N1 pandemics (Lang and Aspinall, 
2012). In addition to the continuing trend 
toward increased life expectancy and the 
shifting demographics, the incidence and 
prevalence of chronic diseases are also 
expected to reach unprecedented levels as 
evidenced from a recent study on individu-
als over 80 years of age, which showed that 
many are living with an increasing number 
of comorbidities (Collerton et al., 2009).
bring their hands in close contact with their 
faces. In humans face touching can occur 
up to almost 40 times per hour (Dimond 
and Harries, 1984). This action as a poten-
tial route of infection becomes important 
when one considers the survival of infec-
tious organisms on inanimate surfaces such 
as handrails, door handles, or lift buttons. 
One recent study reviewed the survival 
of several infectious agents on seemingly 
dry inanimate surfaces and suggested that 
influenza could persist for 1–2 days on such 
surfaces (Kramer et al., 2006). From this it 
would appear that one of the greatest risks 
for becoming infected occurs during peri-
ods of close association with a number of 
individuals some of whom may be infected 
and the greatest likelihood of this occur-
ring could be during periods of travel (Field 
et al., 2010). One distinct change between 
older individuals now compared with pre-
vious generations is that older individu-
als represent a substantial proportion of 
national and international travelers and 
might be at higher risk for some travel-
associated diseases than younger individu-
als (Gautret et al., 2012).
Influenza VaccIne for older 
IndIVIduals; Problems, and 
PersPectIVes
In many countries vaccination with the 
trivalent influenza vaccine (TIV) is recom-
mended for all adults over the age of 60–65 
to combat transmission (Michel et al., 
2009). This vaccine contains three strains 
of inactivated influenza virus (influenza 
A H3N2 and H1N1 and influenza B) and 
whilst this immunization strategy has prob-
ably contributed to saving many lives, the 
exact magnitude of its benefits is still hotly 
debated (Lang et al., 2011). In terms of pro-
tection, studies have shown that TIV led to 
protection in more than 70% of younger 
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the immune system which accrue with age 
would enable us to produce an accumula-
tion of deficits score which could be cor-
related with clinical outcomes (Lang and 
Aspinall, 2012). These could assist us to 
classify individuals into clusters with com-
mon features. So, for example, a portfolio of 
treatments for immunosenescent individu-
als in the cluster characterized by low TREC 
levels who were also CMV positive could 
include therapy to rejuvenate output from 
primary lymphoid organs such as the use of 
interleukin 7 (Aspinall et al., 2007) whilst 
at the same time treating the herpes virus 
infection with a guanosine analog such as 
valaciclovir prior to vaccination. Use of 
such antivirals has provided some inter-
esting results in mouse models. Treatment 
of elderly mice infected with CMV with 
valaciclovir, led to reduced influenza viral 
loads when they were subsequently chal-
lenged with influenza (Beswick et al., 2013). 
Alternatively individuals who are CMV neg-
ative and have both normal for age thymic 
output and T cell function but function-
ally underperforming dendritic cells may be 
recommended to receive the vaccine with 
additional adjuvant.
Such a move from the existing immu-
nization menu toward a greater degree of 
personalized medicine could contribute to 
accelerating the development of new vac-
cines with higher efficacy and of specific 
combined therapeutic approaches than 
those currently available.
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antibody and cell-mediated responses. So in 
this instance, poor responses to vaccine may 
result through the accumulation of multiple 
immune deficits (Lang and Aspinall, 2012).
a PortfolIo aPProach
In a complex system such as the immune 
system with its multiple component over-
laps, predicting individual responsiveness to 
influenza vaccination using a single method 
able to distinguish between a healthy and 
an immunosenescent state, would be very 
challenging. Especially as the ability of the 
immune system to respond to vaccination 
is further impinged upon by the impact of 
non-immune factors such as nutritional 
and metabolic status, and comorbidities 
from which adults increasingly suffer from 
as they age (Collerton et al., 2009).
The presence of these multiple issues 
associated with vaccine ineffectiveness 
underlines the degree of diversity which 
exists amongst older individuals, which in 
turn is somewhat expected since aging is 
neither regulated nor programed. Although 
each individual ages differently and in a 
way, which in part is dependent on lifestyle 
choices and environmental factors, there are 
common threads (Murabito et al., 2012). 
This may provide a route to a better under-
standing of method of protection following 
immunization in the future.
Since there are currently no tests associ-
ated with defining an individual’s ability or 
inability to produce a protective response 
to vaccination, a more valuable approach 
would be to measure several aspects of the 
immune response following vaccination 
within an individual and compare these 
not only with known benchmark levels but 
also to confront these with validated bio-
logical and clinical outcomes. This would 
entail some degree of classification of older 
individuals into specific trends of aging on 
the basis of defined characteristics or their 
absence. In the past efforts have been made 
to achieve this and define an immune risk 
phenotype which includes T cell pheno-
types, subset numbers, function, CMV 
status, and cognitive impairment (Wikby 
et al., 2005). Others have suggested that T 
cell receptor excision circles (TREC) levels 
and may be of interest in this classification 
(Mitchell et al., 2010). Once a characteristic 
is known to be outside the normal range it 
would be considered to be in “functional 
deficit” and the collection of deficits within 
individuals but was ineffective in over half 
of the elderly population (Hannoun et al., 
2004; Monto et al., 2009; Lang et al., 2011). 
Greater resolution of this issue in the past 
has been attempted by holding randomized 
placebo controlled trials (Govaert et al., 
1994), but this approach cannot be consid-
ered further, so the efficacy of the vaccine, 
especially in the elderly, has to be mainly 
derived from observational studies using 
data from research databases or health care 
utilization data systems (Lang et al., 2011).
The poor performance of the TIV in 
providing protection in older individu-
als has been known for some time, but to 
date there has been no satisfactory resolu-
tion of the issue. Several studies have been 
undertaken on possible reasons for this 
problem and these have produced a num-
ber of studies on age-associated changes in 
immunity which have identified problems 
with Langerhans cells (Shaw et al., 2011), 
dendritic cells (Panda et al., 2010), T cell 
function (Saurwein-Teissl et al., 2002), B cell 
function (Sasaki et al., 2011), T and B cell 
repertoires (Yager et al., 2008; Ademokun 
et al., 2011), innate immunity (Shaw et al., 
2010), natural killer cells (Chidrawar et al., 
2006), in addition to how all of these are 
affected by the nutritional status of the 
individual (Langkamp-Henken et al., 2006).
One of the major challenges for vaccine 
development in this population is associ-
ated with identifying measureable surrogate 
markers which are acceptable readouts of 
immune protection (Lang et al., 2011). 
Currently the widely accepted concept of 
protection is associated with post-vacci-
nation antibody levels; a serum antibody 
hemagglutination inhibition (HI) titer 
≥40 UI/L is the level associated with >50% 
reduction of the risk of developing influ-
enza infection after exposure (Hannoun 
et al., 2004). But this correlate of protec-
tion was determined in healthy young 
individuals and not in older people with 
intercurrent comorbidities. In older adults 
other immune parameters actively con-
tribute to protection so that HI titer alone 
may not guarantee immunity or predict 
susceptibility (Lang et al., 2011). This has 
led some authors to consider that no single 
marker should be considered as a surrogate 
of protection especially in a complex mul-
ticomponent system such as the immune 
system and that protection reflects the sum 
of various immune responses, including 
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